ClinicalTrials.gov
ClinicalTrials.gov Menu

School Inner-City Asthma Intervention Study (SICAS-2) (SICAS-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02291302
Recruitment Status : Recruiting
First Posted : November 14, 2014
Last Update Posted : June 23, 2017
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Wanda Phipatanakul, Boston Children’s Hospital

Brief Summary:
The investigators goal is to determine the efficacy of school/classroom based environmental intervention in reducing asthma morbidity in urban schoolchildren.

Condition or disease Intervention/treatment Phase
Asthma Other: integrated pest management Other: air purifier Other: No intervention (control) Phase 4

Detailed Description:
Our proposal builds upon our established, successful school-based infrastructure to determine whether a school/classroom intervention will efficiently and effectively improve asthma morbidity by reducing these exposures. Our goal is to determine the efficacy of school/classroom based environmental intervention in reducing asthma morbidity in urban schoolchildren. Our central hypothesis is that reducing classroom/school exposure to mouse allergen, mold, and particulate pollutants will decrease asthma morbidity in students with asthma. The investigators plan to test this hypothesis in an intervention study of 300 elementary students with asthma from multiple classrooms in inner-city elementary schools. Our clinical trial aims are to determine the effectiveness of a school/classroom based environmental intervention (school integrated pest management and classroom air purifying filter units within these schools) to reduce asthma morbidity. Our mechanistic aim is to test the hypothesis that effects of school/classroom-based environmental interventions on symptoms/other measures of asthma control occur through changes in gene methylation or expression in pathways (and secondarily, in genes) relevant to airway function and asthma. This will expand our understanding of asthma immunopathogenesis and create opportunities to identify potential novel targets for asthma therapy.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: School Inner-City Asthma Intervention Study
Study Start Date : January 2015
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Active Comparator: Environmental Intervention
Active Classroom air purifiers and school integrated pest management environmental intervention
Other: integrated pest management
integrated pest management and environmental strategy

Other: air purifier
air purifiers

Placebo Comparator: Sham and Control
Sham air purifiers and no school integrated pest management environmental intervention
Other: No intervention (control)
no integrated pest management and sham air purifier

Placebo Comparator: Active Air Purifier and Control
Active air purifiers and no school integrated pest management environmental intervention
Other: air purifier
air purifiers

Sham Comparator: Sham and Inegrated Pest
Sham air purifiers and active school integrated pest management
Other: integrated pest management
integrated pest management and environmental strategy




Primary Outcome Measures :
  1. asthma symptoms [ Time Frame: two weeks ]

    Maximum number of

    1. Days with wheezing, tightness in the chest, or cough and/or
    2. Nights with disturbed sleep as a result of asthma and/or
    3. Days on which the child had to slow down or discontinue play activities because of asthma


Secondary Outcome Measures :
  1. health care utilization [ Time Frame: 12 months ]
    Total asthma-related unscheduled visits (UVs) defined as sum of unscheduled clinic visits and emergency department visits, and asthma-related overnight hospitalizations /school year


Other Outcome Measures:
  1. lung function [ Time Frame: 12 months ]
    FEV1; FEV1/FVC* [Secondary indices : (a) FEF25-75. (b) Bronchodilator responsiveness (% change in FEV1 post albuterol)]

  2. degree of exposure reduction [ Time Frame: 12 months ]
    degree of exposure reduction and primary and secondary health outcomes

  3. school absences [ Time Frame: 12 months ]
    Number of school days missed because of asthma/ 2 weeks

  4. composite asthma severity index [ Time Frame: 12 months ]
    Day symptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function, and exacerbations (defined as systemic steroids for asthma )



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   4 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • grades K-8 with asthma attending sampling/intervention schools

Exclusion Criteria:

  • moving schools

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02291302


Contacts
Contact: Wanda Phipatanakul, MD, MS 857-218-5336 wanda.phipatanakul@childrens.harvard.edu
Contact: Amparito Cunningham 857-218-5331 amparito.cunningham@childrens.harvard.edu

Locations
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Wanda Phipatanakul       asthma@childrens.harvard.edu   
Principal Investigator: Wanda Phipatanakul, MD,MS         
Sponsors and Collaborators
Boston Children’s Hospital
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Principal Investigator: Wanda Phipatanakul, MD, MS Boston Children’s Hospital

Responsible Party: Wanda Phipatanakul, Associate Professor of Pediatrics, Boston Children’s Hospital
ClinicalTrials.gov Identifier: NCT02291302     History of Changes
Other Study ID Numbers: U01AI110397 ( U.S. NIH Grant/Contract )
U01AI110397 ( U.S. NIH Grant/Contract )
First Posted: November 14, 2014    Key Record Dates
Last Update Posted: June 23, 2017
Last Verified: June 2017

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases